120 results on '"Kubica, Jacek"'
Search Results
2. Cangrelor — Expanding therapeutic options in patients with acute coronary syndrome
3. The impact of mild therapeutic hypothermia on platelet reactivity in comatose survivors of cardiac arrest with acute myocardial infarction treated with ticagrelor.
4. Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?
5. Comparison of reorganized versus unaltered cardiology departments during the COVID-19 era: a subanalysis of the COV-HF-SIRIO 6 study
6. Mild therapeutic hypothermia or targeted temperature management for cardiac arrest survivors?
7. Opioids and oral P2Y12 receptor inhibitors: A drug–drug interaction
8. Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial
9. Andexanet alfa -- Recommendations for clinical use. Multidisciplinary experts' standpoint.
10. Does ticagrelor effectively inhibit platelets in patients undergoing mild therapeutic hypothermia or it does not?
11. Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022
12. Long-term outcome of rotational atherectomy according to burr-to-artery ratio and changes in coronary artery blood flow: Observational analysis.
13. The impact of mild therapeutic hypothermia on platelet reactivity in comatose survivors of cardiac arrest with acute myocardial infarction treated with ticagrelor
14. IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study
15. Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial
16. Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients.
17. Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients
18. Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study
19. Long-term outcome of rotational atherectomy according to burr-to-artery ratio and changes in coronary artery blood flow: Observational analysis
20. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study
21. Mild therapeutic hypothermia after out-of-hospital cardiac arrest: What does really matter?
22. Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study — preliminary results
23. Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest
24. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines
25. Comparison of temperature measurements in esophagus and urinary bladder in comatose patients after cardiac arrest undergoing mild therapeutic hypothermia
26. Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor -- NARCOTIC trial.
27. Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study.
28. Ion channel inhibition against COVID-19: A novel target for clinical investigation
29. Oral NAloxone to overcome the moRphine effect in acute COronary syndrome patients treated with TICagrelor — NARCOTIC trial
30. ISAR-REACT 5 — What have we learned?
31. Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society
32. Influence of QRS duration and axis on response to cardiac resynchronization therapy in chronic heart failure with reduced left ventricular ejection fraction: A single center study including patients with left bundle branch block.
33. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts’ standpoint
34. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up
35. Influence of cardiac resynchronization therapy on oxidative stress markers in patients with chronic heart failure
36. Off-target effects of glycoprotein IIb/IIIa receptor inhibitors
37. Influence of QRS duration and axis on response to cardiac resynchronization therapy in chronic heart failure with reduced left ventricular ejection fraction: A single center study including patients with left bundle branch block
38. Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized clinical trials
39. Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology.
40. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome.
41. Usefulness of optical coherence tomography in the assessment of atherosclerotic culprit lesions in acute coronary syndromes. Comparison with intravascular ultrasound and virtual histology.
42. Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report.
43. In search of understanding the endothelium.
44. The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease.
45. Immunoglobulin E in patients with ischemic heart disease.
46. The reliability of noninvasive cardiac output measurement using the inert gas rebreathing method in patients with advanced heart failure.
47. Smokers versus non-smokers undergoing percutaneous transluminal coronary angioplasty: The impact of clinical and procedural characteristics on in-hospital mortality.
48. Immunoglobulin E as a marker of the atherothrombotic process in patients with acute myocardial infarction.
49. Percutaneous coronary angioplasty in elderly patients: Assessment of in-hospital outcomes.
50. One-year outcomes of left main coronary artery stenting in patients with cardiogenic shock.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.